0 146

Cited 20 times in

Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy.

DC FieldValueLanguage
dc.contributor.author김종윤-
dc.contributor.author박희남-
dc.contributor.author엄재선-
dc.contributor.author이문형-
dc.contributor.author정보영-
dc.date.accessioned2017-02-24T03:06:46Z-
dc.date.available2017-02-24T03:06:46Z-
dc.date.issued2016-
dc.identifier.issn0167-5273-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/146245-
dc.description.abstractBACKGROUND: The efficacy of oral anticoagulation therapy (OAT) has not been revealed in atrial fibrillation (AF) patients with newly diagnosed cancers. This study evaluated the thromboembolic and bleeding events in AF patients with malignancies according to OAT. METHODS AND RESULTS: In 2168 consecutive non-valvular AF patients with newly diagnosed malignancies, we analyzed the composite endpoints including major adverse cardiac events (MACEs) and major bleeding. Based on a propensity score matching, two groups with 690 matched pairs were created. Patient baseline characteristics were comparable between the matched groups. During a follow-up period of 3.9 ± 2.8 years, 72 (10%) and 65 (9%) patients had MACEs in the propensity score-matched OAT + and OAT − groups, respectively (p = 0.461). There was no significant difference in the major bleeding (10% vs. 8%, p = 0.300) and composite endpoints (18% vs. 16%, p = 0.181) between OAT + and OAT − patients. During the first year after the cancer diagnosis, 66 (48%) MACEs, 52 (41%) major bleedings, and 116 (49%) composite end points of all events occurred. The optimal international normalized ratio (2.0 to 3.0) level was achieved in only 85 (12%) patients. However, 1 year after cancer diagnosis, OAT + patients with the target therapeutic range of ≥ 60% demonstrated better cumulative survival free of composite end point than OAT − patients (p = 0.026). CONCLUSION: During the first year after the cancer diagnosis, OAT did not improve the composite end point because of poor INR control caused by cancer treatment. However, after 1 year after diagnosis of cancer, optimal anticoagulation significantly reduced the composite end point.-
dc.description.statementOfResponsibilityrestriction-
dc.format.extent372~378-
dc.languageEnglish-
dc.publisherElsevier-
dc.relation.isPartOfINTERNATIONAL JOURNAL OF CARDIOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdministration, Oral-
dc.subject.MESHAged-
dc.subject.MESHAnticoagulants/administration & dosage-
dc.subject.MESHAnticoagulants/adverse effects*-
dc.subject.MESHAtrial Fibrillation/complications-
dc.subject.MESHAtrial Fibrillation/drug therapy*-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHemorrhage/chemically induced*-
dc.subject.MESHHemorrhage/epidemiology-
dc.subject.MESHHumans-
dc.subject.MESHIncidence-
dc.subject.MESHMale-
dc.subject.MESHNeoplasms/complications-
dc.subject.MESHNeoplasms/drug therapy*-
dc.subject.MESHRepublic of Korea/epidemiology-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHRisk Assessment/methods*-
dc.subject.MESHRisk Factors-
dc.subject.MESHStroke/etiology-
dc.subject.MESHStroke/prevention & control*-
dc.subject.MESHSurvival Rate/trends-
dc.subject.MESHTime Factors-
dc.titleBleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy.-
dc.typeArticle-
dc.publisher.locationNetherlands-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorYong-Joon Lee-
dc.contributor.googleauthorJin-kyu Park-
dc.contributor.googleauthorJae-Sun Uhm-
dc.contributor.googleauthorJong-Yun Kim-
dc.contributor.googleauthorHui-Nam Pak-
dc.contributor.googleauthorMoon-Hyoung Lee-
dc.contributor.googleauthorJung-Hoon Sung-
dc.contributor.googleauthorBoyoung Joung-
dc.identifier.doi10.1016/j.ijcard.2015.10.166-
dc.contributor.localIdA00926-
dc.contributor.localIdA01776-
dc.contributor.localIdA02337-
dc.contributor.localIdA02766-
dc.contributor.localIdA03609-
dc.relation.journalcodeJ01093-
dc.identifier.eissn1874-1754-
dc.identifier.pmid26539960-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0167527315307300-
dc.subject.keywordAnticoagulation-
dc.subject.keywordAtrial fibrillation-
dc.subject.keywordCancer-
dc.subject.keywordHemorrhage-
dc.subject.keywordStroke-
dc.contributor.alternativeNameKim, Jong Youn-
dc.contributor.alternativeNamePak, Hui Nam-
dc.contributor.alternativeNameUhm, Jae Sun-
dc.contributor.alternativeNameLee, Moon Hyoung-
dc.contributor.alternativeNameJoung, Bo Young-
dc.contributor.affiliatedAuthorKim, Jong Youn-
dc.contributor.affiliatedAuthorPak, Hui Nam-
dc.contributor.affiliatedAuthorUhm, Jae Sun-
dc.contributor.affiliatedAuthorLee, Moon Hyoung-
dc.contributor.affiliatedAuthorJoung, Bo Young-
dc.citation.volume203-
dc.citation.startPage372-
dc.citation.endPage378-
dc.identifier.bibliographicCitationINTERNATIONAL JOURNAL OF CARDIOLOGY, Vol.203 : 372-378, 2016-
dc.date.modified2017-02-24-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.